X

Drug Profile

Anti-Ras antibody gene therapy

Alternative Names: AV1Y28 anti-Ras antibody gene therapy

Latest Information Update: 05 Mar 2008

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Introgen Therapeutics
Developer Introgen Therapeutics; University of Texas M. D. Anderson Cancer Center
Class Antineoplastics; Gene therapies
Mechanism of Action Ras protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer

Most Recent Events

04 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
10 Jan 2001 Preclinical development for Cancer in USA (Unknown route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com